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Background: Hyponatremia is the most common electrolyte imbalance encountered in clinical practice, associated
with increased mortality and length of hospital stay. However, no high-quality evidence regarding whether hypertonic
saline is best administered as a continuous infusion or a bolus injection has been found to date. Therefore, in the
current study, we will evaluate the efficacy and safety of rapid intermittent correction compared with slow continuous
correction with hypertonic saline in patients with moderately severe or severe symptomatic hyponatremia.
Methods/design: This is a prospective, investigator-initiated, multicenter, open-label, randomized controlled study
with two experimental therapy groups. A total of 178 patients with severe symptomatic hyponatremia will be enrolled
and randomly assigned to receive either rapid intermittent bolus or slow continuous infusion management with
hypertonic saline. The primary outcome is the incidence of overcorrection at any given period over 2 days. The
secondary outcomes will include the efficacy and safety of two other approaches to the treatment of hyponatremia
with 3% hypertonic saline.
Discussion: This is the first clinical trial to investigate the efficacy and safety of rapid intermittent correction compared
with slow continuous correction with hypertonic saline in patients with moderately severe or severe hyponatremia.
Trial registration: ClinicalTrials.gov, identifier number: NCT02887469. Registered on 1 August 2016.
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Hyponatremia is the most common electrolyte imbalance
encountered in clinical practice, and is associated with
increased mortality and length of hospital stay [1]. The
symptoms related to hyponatremia span a broad range
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coma, and epilepsy) [2–5]. Treatment strategies for
hyponatremia differ according to the severity of clinical
symptoms and duration of hyponatremia [6]. The extent
and rate of increase in serum sodium (sNa) levels during
treatment are crucial. Overcorrection of chronic hypona-
tremia may result in osmotic demyelination syndrome
(ODS), whereas undercorrection may be insufficient to
prevent its life-threatening manifestations [6–9].
Several methods for continuous infusion of hypertonic
saline have been used to guide the rate of fluidle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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The increase in sNa should be limited to 8–10 mmol/L
within the first 24 h and 18 mmol/L within 48 h [11,
12]. As these methods were based on static models of
a dynamic clinical situation, they had a bias toward
overcorrection of hyponatremia [1, 13–15].
Recent guidelines have recommended prompt infusion
of 100–150 mL of 3% saline over 10–20 min to increase
the sNa by 4–6 mmol/L during the first hour. A pragmatic
approach to treatment with hypertonic fluid is to use
small, fixed boluses to achieve controlled incremental in-
creases in sNa [1, 13–17]. However, this recommendation
was the result of small randomized trials [18], case reports
with small numbers of patients [14, 19], and expert
opinion [20–23]. No high-quality evidence has been
reported regarding whether hypertonic saline is best
administered as a continuous infusion (preferred by most)
or as a rapid intermittent bolus injection. The purpose of
the present study was to investigate the efficacy and safety
of rapid intermittent correction compared with slow con-
tinuous correction with hypertonic saline in patients with
symptomatic severe hyponatremia. Furthermore, the study
will examine prevailing conceptions regarding the optimal
treatment of severe symptomatic hyponatremia.
Methods/design
Hypothesis
The use of intermittent bolus therapy with 3% sodium
chloride will prevent and/or ameliorate ODS in patients
with hyponatremia treated with hypertonic saline. Com-
pared to the use of standard slow continuous infusion
with 3% hypertonic saline, the incidence of overcorrec-
tion will be lower in patients with moderately severe or
severe hyponatremia.
Study design
This study is a prospective, investigator-initiated, multicen-
ter, open-label, randomized controlled study with two ex-
perimental therapy groups. We have followed the Standard
Protocol Items: Recommendations for Interventional Trials
(SPIRIT) 2013 Statement which defines standard protocol
items for clinical trials [24] (see Additional file 1). The study
algorithm is depicted in Fig. 1 and the SPIRIT and study
schedule are given in Figs. 2 and 3. After enrollment, clin-
ical follow-up will be performed 2 days after treatment with
3% hypertonic saline.
Study participants and measurements
All participants will be selected from among patients visi-
ting the emergency rooms of two general hospitals in
Korea (Seoul National University Bundang Hospital, Seoul
National University Boramae Medical Center). Patients
aged over 18 years who have moderately severe to severe
symptoms and glucose-corrected sNa [25] ≤125 mmol/Lon the first blood test will be screened for study participa-
tion. Moderate symptoms include nausea, headache,
drowsiness, general weakness, and malaise [1, 26, 27].
Severe symptoms include vomiting, stupor, seizure, and
coma (Glasgow Coma Scale (GCS)).
The following assessments will be performed during the
initial emergency room encounter: (1) completion of
questionnaire on medical and drug history including the
use of antihypertensive medication, diuretics, nonsteroidal
anti-inflammatory drugs, selective serotonin reuptake in-
hibitors, antiepileptic drugs, steroids, and synthyroid, (2)
physical examination of all body systems, (3) measure-
ment of height and weight, (4) blood pressure and pulse
rate measurement, and (5) assessment of psychological
status. Participants, who meet all of the inclusion criteria,
do not require exclusion on the basis of the exclusion cri-
teria, and provide written informed consent will be eligible
for this study (Table 1).
Serum creatinine (SCr) will be measured using the
isotope dilution mass spectrometry-traceable method with
a Toshiba TBA 200FR Analyzer (Toshiba, Tokyo, Japan).
The estimated glomerular filtration rate (eGFR) will be
calculated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD EPI) equation [28].
Randomization
A research coordinator will perform the randomization. A
list of random numbers will be generated by an indepen-
dent statistician. Eligible participants will be randomly
assigned 1:1 to either the slow continuous correction
group or the rapid intermittent correction group in
accordance with the predefined randomization list with a
block size of 2. Randomization will be stratified based on
the symptom severity related to hyponatremia (moderately
severe or severe).
Physician’s practical treatment guidelines according to
the sNa level
The principal purpose of this study will be to com-
pare the rapid intermittent correction group to the
slow continuous correction group [29]. According to
a review of the medical literature on the treatment of
hyponatremia, treatment with hypertonic (3%) saline
is recommended in cases of severe symptomatic
hyponatremia [1, 15, 16]. Therefore, the rate of infu-
sion of 3% saline will be stratified based on the
symptom severity in each group. After randomization,
the participants will undergo either rapid intermittent
correction or slow continuous correction of hypona-
tremia for 48 h. Treatment in the intermittent bolus
group will comply with European guidelines published
in 2014, and the slow continuous infusion will be guided
by widely accepted methods [1, 13–16]. The treatment
goals are to raise the sNa level by 5–9 mmol/L from the
All patients with moderately severe or severe hyponatremia at ER
Excluded
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Fig. 1 Study algorithm. ER emergency room
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24 h, and to raise the sNa level by 10–17 mmol/L from
the initial sNa or ≤130 mmol/L, and to achieve symp-
tom relief during the 48 h [10–12]. We will also
check for overcorrection at every sample time point
and conduct relowering treatment. Relowering treat-
ment is performed as below if the achieved sNa level
is ≥10 mmol/L at any sample time point within the
first 24 h or the achieved sNa level is ≥18 mmol/L at
any sample time point within 48 h [1, 13–16]. The
treatment goal, relowering treatment strategy, and
cause-specific treatment of hyponatremia will be ap-
plied to each group equally.Fig. 2 Schedule of enrollment, interventions, and assessments according to
Trials (SPIRIT) guideline. GCS Glasgow Coma ScaleRapid intermittent bolus group (Fig. 4a)
First 24 hours
In the case of moderately severe symptoms, the use of
intravenous infusion of 2 mL/kg 3% hypertonic saline over
20 min (100 mL, 3% saline for unknown body weight) is
recommended. In cases of severe symptoms, it is recom-
mended to perform intravenous infusion of 4 mL/kg 3%
hypertonic saline over 40 min (200 mL, 3% saline for un-
known body weight). After the initial treatment, repeated
infusion of 2 mL/kg 3% hypertonic saline over 20 min at
every sample time point (at 1, 6, 12, 18, and 24 h) until
the observation of a sNa level increase of 5–9 mmol/L
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Fig. 3 Study schedule. R randomization, ER emergency room, CBC complete blood count, Glu glucose, AST aspartate aminotransferase, ALT
alanine aminotransferase, Chol cholesterol, BUN blood urea nitrogen, Cr creatinine, tCO2 total CO2, TFT thyroid function test, ACTH rapid
adrenocorticotropic hormone, Osm Osmolality, U/A urinalysis, E' electrolyte, UOsm Urine osmolality, GCS Glasgow Coma Scale
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In both moderately severe and severe cases of hyponatre-
mia, repeated infusion of 2 mL/kg 3% hypertonic saline
over 20 min at every sample time point (at 30, 36, 42, and
48 h) is recommended until the sNa level increases to 10–
17 mmol/L from the initial sNa or until the sNa reaches
130 mmol/L, and until the symptoms improve.
Slow continuous correction group (Fig. 4b)
First 24 hours
In the case of moderately severe symptoms, it is rec-
ommended to infuse 3% hypertonic saline at a rate ofTable 1 Inclusion and exclusion criteria
Inclusion criteria
18 years and older
Glucose-corrected serum sodium ≤125 mmol/L
Symptomatic patients
Moderately severe:
nausea without vomiting, drowsiness, headache,
general weakness, malaise
Severe:
vomiting, stupor, seizures, coma (GCS ≤8)
GCS Glasgow Coma Scale, SBP systolic blood pressure, MAP mean arterial pressure,
coronary angioplasty0.5 mL/kg/h (25 mL/h, 3% saline for unknown body
weight). In cases of severe symptoms, it is recom-
mended to begin an infusion of 3% hypertonic saline
at a rate of 1 mL/kg/h (50 mL/h, 3% saline for
unknown body weight). After the initial treatment,
the infusion protocol will be modified as below ac-
cording to the sNa level at every sample time point
(at 1, 6, 12, 18, and 24 h). If the sNa level increases
to 5–9 mmol/L above the initial sNa level, accompan-
ied by symptom relief, the 3% saline infusion should
be discontinued regardless of changes in the sNa
level. If the sNa level increases at a rate of underExclusion criteria
Pseudo-hyponatremia (serum osmolality >275 mOsm/kg)
Primary polydipsia (urine osmolality ≤100 mOsm/kg)
Glucose-corrected serum sodium >125 mmol/L
Initial arterial hypotension (SBP <90 mmHg and MAP <70 mmHg)
Anuria or urinary outlet obstruction
Decompensated LC (LC with ascites or diuretics use or history of
hepatic encephalopathy and varices)
Bilirubin >2 mg/dL, transaminase levels >2.5 times the upper limit
of normal)
Uncontrolled diabetes mellitus (HbA1C >9%)
Women who are pregnant or breastfeeding
Within the 3 months prior to randomization, history of cardiac surgery
excluding PCA, acute myocardial infarction, sustained ventricular
tachycardia, ventricular fibrillation, acute coronary syndrome,
cerebrovascular trauma, and increased intracranial pressure
LC liver cirrhosis, HbA1C glycosylated hemoglobin, PCA percutaneous
ab
Fig. 4 Treatment. a Rapid intermittent correction with hypertonic saline in patients with moderately severe or severe symptomatic hyponatremia.
min minute, Na sodium, bwt body weight. ↑, increase. b Slow continuous correction with hypertonic saline in patients with moderately severe or
severe symptomatic hyponatremia. hr hour, Na sodium, bwt body weight. ↑, increase; Δ, delta – change in amount
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add 3% hypertonic saline infusion at a rate of
0.25 mL/kg/h to the previous infusion rate or to re-
start the infusion at 0.5 mL/kg/h if it was previously
discontinued. If the sNa level demonstrates increases
of over 0.5 mmol/h or 3 mmol/6 h, the rate of 3%
hypertonic saline infusion should be maintained.From 24 to 48 hours
The infusion protocol will be modified as below ac-
cording to the sNa levels at every sample time point
(at 30, 36, 42, and 48 h). If the Na level increases to
10–17 mmol/L above the initial sNa level or sNa
reaches 130 mmol/L, and symptom relief is observed,
the 3% hypertonic saline infusion should be
Lee et al. Trials  (2017) 18:147 Page 6 of 9discontinued regardless of changes in the sNa level
during the previous 6 h. If the Na level increase is
less than 1.5 mmol/6 h, it is recommended to add 3%
hypertonic saline infusion at a rate of 0.25 mL/kg/h
to the previous infusion rate or to restart the infusion
at a rate of 0.25 mL/kg/h if it was previously discon-
tinued. If sNa levels increase at a rate of over
1.5 mmol/6 h, the 3% saline infusion rate should be
maintained.
Outcome measures
The primary outcome is the incidence of overcorrection,
a surrogate marker of ODS, at any given period, defined
as follows: increase in sNa level by >12 mmol/L within
the first 24 h or increase in sNa level by >18 mmol/L
within 48 h. The secondary outcomes will include
efficacy and safety; changes in symptoms between
pretreatment and 24 and 48 h after treatment with 3%
hypertonic saline; time from treatment initiation to an
increase in sNa ≥5 mmol/L; time from treatment initi-
ation to the achievement of a sNa >130 mmol/L; inci-
dence of target correction rate, defined as an achieved
sNa <10 mmol/L within 24 h and a sNa <18 mmol/L
within 48 h; length of hospital stay; incidence of add-
itional treatment; incidence of ODS confirmed by the
International Classification of Disease, 10th Revision
(ICD-10) code or magnetic resonance imaging (MRI); in-
cidence of relowering treatment; and change in GCS
score between pretreatment and 24 and 48 h after 3%
hypertonic saline treatment.
Clinical and laboratory evaluations
The physical examination, laboratory evaluations, and
medication reviews will be conducted before treatment;
the laboratory evaluations will include a complete blood
count, serum electrolytes, blood urea nitrogen, creatinine,
calcium, phosphorous, protein, albumin, and glucose; a
liver function test; a thyroid function test (TFT); rapid
adrenocorticotropic hormone (ACTH) test (basal cortisol,
ACTH, cortisol at 30 min and 60 min), serum osmolality;
urinalysis, urine electrolytes, urine osmolality. sNa levels
will be measured every 6 h for 2 days [30]. The GCS score
will be assessed before treatment and at 24 and 48 h of
treatment. All types and volumes of administered fluid
during 48 h will be monitored.
Safety issues
All adverse events related to overcorrection will be re-
corded and followed up during the study period or until
resolution during treatment with 3% hypertonic saline. Any
serious adverse events will be reported to investigators and
the Ethics Committee. We will check for overcorrection at
every sample time point and conduct relowering treatment
as needed. Relowering treatment is performed as follows ifthe achieved sNa level is ≥10 mmol/L at any sample time
point within the first 24 h or if the achieved sNa level is
≥18 mmol/L at any sample time point within 48 h: discon-
tinuing ongoing active treatment; initiating infusion of
10 mL/kg of 5% dextrose over 1 h; and/or adding desmo-
pressin 2 mcg [1].
Sample size calculation
In the medical literature, ODS is a critically important
outcome, but the incidence of ODS is very low [1, 15, 31].
Therefore, as a surrogate marker of ODS, the rate of
overcorrection >12 mmol/L within 24 h or >18 mmol/L
within 48 h was calculated for the primary study outcome.
A previous study reported that the overcorrection rate
was 10–16% with slow continuous correction of hypona-
tremia [10]. However, there was insufficient information
for estimating the rate of overcorrection with intermittent
bolus infusion. Based on clinical practice and experience,
we estimated that the overcorrection rate was 32% with
slow continuous correction during a recent 1-year period.
We therefore expect that the rate of overcorrection will be
5% in patients treated with rapid intermittent correction
and the rate of overcorrection with slow continuous
correction could be as high as 20%. We calculated the re-
quired sample size for an estimated dropout rate of 15%, a
two-sided level of significance of α = 5%, a power of 80%,
and found that 89 participants will be required in
each group to find a significant difference using a χ2
test. A total of 178 participants will be included in
the analysis. We have considered one interim analysis
at the time that a half of subjects complete the study.
The O’Brien-Fleming’s alpha spending function will
be used to test the first interim and final analysis of
primary outcome.
Statistical analyses
Statistical analyses will be performed on both per-protocol
(PP) and intention-to treat (ITT) bases. For the PP
analysis, all participants who completed the study will be
included to evaluate the primary and secondary outcomes.
For the ITT analysis, all participants who were enrolled
and randomized to one of the two groups will be included.
The baseline characteristics and laboratory data will be
presented as means and standard deviations for continu-
ous variables and as frequencies and percentages for
categorical variables.
The incidence of overcorrection, ODS, relowering
treatment, and target correction rate (achieved sNa
<10 mmol/L within the first 24 h and sNa <18 mmol/L
within 48 h) will be compared between the two groups
using a χ2 test and Fisher’s exact test. In interim analysis,
if the P value < 0.003 then we would stop the study early
for significance of outcome. If not, we would recruit an-
other half of subjects. The differences in changes in
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and 48 h, time to reach target sNa, time to achieved sNa
≥5 mmol/L for the first time, and length of hospital stay will
be analyzed using Student’s t test or the Mann-Whitney U
test. A value of P < 0.05 will be considered statistically
significant. All analyses will be performed using SPSS Statis-
tics software V21.0 (IBM Corporation, Armonk, NY, USA).
Data and safety monitoring
The paper data collection sheets and signed informed
consents will be stored in a locked cabinet, and the elec-
tronic data base will be stored on password-protected
secure severs. Any unanticipated adverse events that
occur during the study will be reported to the Institu-
tional Review Board in accordance with the procedures
of Seoul National University Bundang Hospital, Korea.
For any revised study procedure, the modification will
be submitted to the Seoul National University Bundang
Hospital Institutional Review Board for approval and to
ClinicalTrials.gov. The data will be kept confidential
with only limited access to research investigators.
Discussion
Recently published guidelines recommended the prompt
infusion of small, fixed boluses of hypertonic saline in
patients with symptomatic hyponatremia [1, 15, 16].
This regimen leads to abrupt incremental increases in
sNa levels and improvement of hyponatremia-related
symptoms [1, 15, 16]. However, safety issues regarding
rapid correction with hypertonic saline have not been
evaluated. No large-scale randomized controlled trials to
evaluate and compare the efficacy and safety of rapid
and slow correction with hypertonic saline have been
performed. This is the first clinical trial to provide
physicians with quality evidence regarding treatment
with hypertonic saline in patients with moderately severe
or severe hyponatremia. In addition, a protocolized
approach, such as that of this study, may be extended to
the management of other electrolyte disorders.
In the development of this protocol, we complied with
recent guidelines, particularly in determining the target
sNa levels, in the method of infusion of 3% hypertonic
saline for the rapid correction group, and in the
classification of symptoms of hyponatremia [1, 15, 16].
Recently published guidelines recommended prompt
intravenous infusion of 100–150 mL 3% hypertonic saline
over 10–20 min, repeated once or twice as needed, in the
initial treatment of severe hyponatremia [1, 15, 16]. We
adopted a weight-based approach (2 mL/kg) rather than
the fixed 100–150-mL infusion volumes of 3% hypertonic
saline in this study because Koreans tend to have smaller
physiques than Westerners. Recent guidelines recom-
mended discontinuing the infusion of hypertonic saline in
cases of improvement of symptoms after a 5-mmol/Lincrease in sNa and initiating a diagnosis-specific treat-
ment [1]. Our planned approach to decreases or no
change in sNa levels during the diagnosis of hypona-
tremia and the initiation of cause specific treatment
was to repeat a bolus infusion every 6 h until sNa in-
crementally increases to the target level and symptom
relief were observed. This approach is different from
the protocols recommended by recent guidelines [1].
In the slow continuous correction group, we adopted
a 3% hypertonic saline infusion rate of 0.5–1 mL/kg/
h, a widely known treatment approach [10, 11], accor-
ding to symptom severity. Recent guidelines define
indicative symptoms of cerebral edema as severe or
moderate symptoms that can be attributed to hypona-
tremia [1]. In our study, general weakness and
malaise, usually considered nonspecific, were included
as moderate symptoms of hyponatremia. Our ration-
ale for including these as symptoms of hyponatremia
are as follows: first, patients start complaining of
nausea and malaise as sNa concentration falls acutely
below 125 mmol/L [27]. Malaise is thus a result of
hyponatremia and is as significant as nausea. Second,
patients with symptomatic hyponatremia, including
weakness and malaise, should be treated with
hypertonic saline [26]. As this clinical trial aims to
compare the efficacy and safety of rapid versus slow
hypertonic saline administration in the correction of
hyponatremia, we included general weakness and
malaise as hyponatremia-defining symptoms.
A previous study reported that the overcorrection rate
was 10–16% in slow continuous correction of hypona-
tremia [10]. According to unpublished retrospective
data in our hospital, overcorrection in the slow con-
tinuous correction group occurred in approximately
32% out of 129 hyponatremic patients during a recent
1-year period. Although Moritz et al. reported that
there is little or no risk of inadvertent overcorrection
[20], data on the rapid intermittent correction regimen
were unavailable. We therefore expect that the overcor-
rection rate will be 5% in patients treated with rapid
intermittent correction, and the overcorrection rate in
slow continuous correction could be as high as 20%.
For this reason, we will plan to perform an interim
analysis, which will be conducted after a number of pa-
tients equal to half the estimated total sample size have
been enrolled. No previous studies addressing differ-
ences in efficacy between rapid intermittent correction
groups and slow continuous correction groups in each
stratification group have been reported. In the interim
analysis, we will also examine the ratio of stratification
(moderately severe versus severe) for each experimental
therapy group and analyze the efficacy of rapid
intermittent correction compared to slow continuous
correction for each level of stratification. After the
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patients will be adjusted to the ratio of stratification in
the experimental therapy groups. In the interim ana-
lysis, if the P value < 0.003 then we will stop the study
early for significance of outcome. If not, we will recruit
another half of subjects.
We will also include the participants with chronic
hyponatremia. It is well-known that using a threshold of
48 h is frequently applied to distinguish “acute” from
“chronic” hyponatremia [1]. Because not all patients
have sNa measured within 48 h prior to visiting the
emergency room. Therefore, it is practically impossible
to exclude the patients with chronic hyponatremia based
on these definitions. Second, the most important factor
in determining treatment of hyponatremia is the pres-
ence of symptoms, irrespective of biochemical degree or
timing (acute versus chronic) of hyponatremia [1]. We
will enroll the patients with moderately severe to severe
symptoms who need to be treated. In other words, even
if the patients belong to the chronic hyponatremia
group, the patients with symptomatic hyponatremia
need to be treated. Therefore, we thought that including
the patients with chronic hyponatremia is reasonable
and inevitable.
We will use the overcorrection rate as a primary
outcome. ODS is a serious complication, which should
be prevented for patient safety, and it is one of the
critical outcomes in the management of hyponatremia,
but it is difficult to diagnose and very uncommon [1, 31].
Several studies have reported that the rate of overcorrec-
tion is strongly correlated with ODS, and is highly sensi-
tive for predicting ODS. In terms of safety issues, the
overcorrection rate might be a good laboratory outcome
in our trial [1, 15, 32, 33].
This trial may have some limitations. We will enroll pa-
tients who visit the emergency room in general hospitals;
therefore, patients with hospital-acquired hyponatremia
will be excluded. Second, various situations may affect
protocol violations, considering that on-duty physicians
and nurses may work in shifts. For this, reason we made
both protocols as simple as possible.
In summary, the SALSA study is the first prospec-
tive, multicenter, randomized, open-label, controlled
clinical trial to evaluate the clinical usefulness of
rapid intermittent correction management in patients
with moderately severe or severe hyponatremia. The
aim of this study is to evaluate the efficacy and safety
of rapid bolus correction compared with slow con-
tinuous correction of hyponatremia.Trial status
This trial started recruiting in August 2016. Recruitment
is expected to conclude by July 2018.Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical protocol and related documents. (DOC 122 kb)
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